HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,895,484 | +9.5% | 75,798 | +2.9% | 0.01% | 0.0% |
| Q2 2023 | $2,645,167 | -11.0% | 73,659 | -5.3% | 0.01% | -14.3% |
| Q1 2023 | $2,970,761 | -20.4% | 77,789 | +18.6% | 0.01% | -30.0% |
| Q4 2022 | $3,732,982 | +44.1% | 65,606 | +0.1% | 0.01% | +42.9% |
| Q3 2022 | $2,591,000 | +19.5% | 65,529 | +33.0% | 0.01% | +16.7% |
| Q2 2022 | $2,169,000 | +539.8% | 49,283 | +492.2% | 0.01% | +500.0% |
| Q3 2021 | $339,000 | +3.0% | 8,322 | +14.9% | 0.00% | 0.0% |
| Q2 2021 | $329,000 | +7.2% | 7,241 | -1.7% | 0.00% | 0.0% |
| Q1 2021 | $307,000 | -20.1% | 7,364 | -18.0% | 0.00% | 0.0% |
| Q4 2020 | $384,000 | +71.4% | 8,979 | +5.5% | 0.00% | 0.0% |
| Q3 2020 | $224,000 | -87.3% | 8,512 | -91.6% | 0.00% | -98.3% |
| Q4 2015 | $1,759,000 | +85.4% | 101,492 | +43.7% | 0.06% | +48.7% |
| Q3 2015 | $949,000 | +16.0% | 70,624 | +95.0% | 0.04% | +50.0% |
| Q2 2015 | $818,000 | -17.0% | 36,224 | -47.5% | 0.03% | -21.2% |
| Q1 2015 | $985,000 | – | 68,976 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |